one8zero8 LLC bought a new stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 8,600 shares of the medical equipment provider's stock, valued at approximately $620,000.
Several other hedge funds and other institutional investors have also made changes to their positions in the company. First Horizon Advisors Inc. boosted its holdings in Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock worth $39,000 after buying an additional 134 shares in the last quarter. Brooklyn Investment Group boosted its holdings in Hologic by 14.7% during the fourth quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider's stock worth $82,000 after buying an additional 145 shares in the last quarter. Empirical Finance LLC lifted its holdings in shares of Hologic by 1.8% in the third quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider's stock valued at $690,000 after purchasing an additional 147 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after purchasing an additional 159 shares in the last quarter. Finally, Trivant Custom Portfolio Group LLC lifted its holdings in shares of Hologic by 2.1% in the fourth quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider's stock valued at $602,000 after purchasing an additional 169 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.
Analysts Set New Price Targets
A number of equities analysts have recently weighed in on HOLX shares. Leerink Partnrs lowered shares of Hologic from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 6th. Leerink Partners lowered shares of Hologic from an "outperform" rating to a "market perform" rating and dropped their price target for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th. Jefferies Financial Group began coverage on shares of Hologic in a research report on Tuesday, December 10th. They set a "hold" rating and a $85.00 price target for the company. Citigroup dropped their price target on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Finally, Morgan Stanley dropped their price target on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $84.62.
Get Our Latest Report on HOLX
Hologic Stock Down 0.7 %
Shares of HOLX stock traded down $0.46 on Thursday, hitting $61.01. The stock had a trading volume of 3,109,732 shares, compared to its average volume of 1,722,375. The firm has a market capitalization of $13.69 billion, a price-to-earnings ratio of 19.25, a P/E/G ratio of 2.14 and a beta of 0.97. The stock's 50 day moving average is $66.50 and its 200-day moving average is $74.28. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic, Inc. has a 52-week low of $60.34 and a 52-week high of $84.67.
Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.
About Hologic
(
Free Report)
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
See Also
Before you consider Hologic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.
While Hologic currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
